Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1997-1-7
|
pubmed:abstractText |
The stability and excretion of [14C]-gadodiamide (GdDTPA-BMA) was studied in male rats after i.v. injection of 0.3 mmol/kg [14C]-GdDTPA-BMA (Gd-diethylenetriaminepentaacetic-acid-bis-methylamide) formulated as gadodiamide injection (OMNISCAN, Nycomed Imaging AS, Oslo, Norway). Samples of blood and urine obtained within 60 min and 6 h postdosing, respectively, were analyzed for radiolabeled compounds. Analysis of GdDTPA-BMA in high and low molecular weight fractions of serum indicated no protein binding. HPLC analyses of urine samples obtained 0-2 h, 2-4 h and 4-6 h after injection revealed no detectable amounts of biotransformation products of GdDTPA-BMA. Serum samples obtained 30 min and 60 min after injection contained 9-13 microM of an unidentified compound which had a retention time different from all conceivable metabolites of gadodiamide. A similar concentration of this unknown compound was found in spiked predose serum samples. The total amount of the unknown compound in serum was less than 1% of the injected dose of [14C]-gadodiamide injection. It is concluded that gadodiamide, when administered i.v. as gadodiamide injection at a dosage of 0.3 mmol/kg, is stable in vivo and that the very major part of the dose (> 99%) is excreted in urine as an unchanged complex.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Contrast Media,
http://linkedlifedata.com/resource/pubmed/chemical/Gadolinium DTPA,
http://linkedlifedata.com/resource/pubmed/chemical/Organometallic Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Pentetic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/gadodiamide
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0378-7966
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
20
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
307-13
|
pubmed:dateRevised |
2011-2-2
|
pubmed:meshHeading |
pubmed-meshheading:8983938-Animals,
pubmed-meshheading:8983938-Biotransformation,
pubmed-meshheading:8983938-Chromatography, High Pressure Liquid,
pubmed-meshheading:8983938-Contrast Media,
pubmed-meshheading:8983938-Drug Stability,
pubmed-meshheading:8983938-Gadolinium DTPA,
pubmed-meshheading:8983938-Injections, Intravenous,
pubmed-meshheading:8983938-Male,
pubmed-meshheading:8983938-Organometallic Compounds,
pubmed-meshheading:8983938-Pentetic Acid,
pubmed-meshheading:8983938-Rats,
pubmed-meshheading:8983938-Rats, Wistar
|
pubmed:articleTitle |
In vivo stability and excretion of gadodiamide (GdDTPA-BMA), a hydrophilic gadolinium complex used as a contrast enhancing agent for magnetic resonance imaging.
|
pubmed:affiliation |
Research and Development, Nycomed Imaging AS, Oslo, Norway.
|
pubmed:publicationType |
Journal Article
|